To access the event via conference call, please dial 800-715-9871 (domestic) or 646 307-1963 (international) and reference the conference ID number 3567655. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. About Seres Therapeutics Seres Therapeutics, Inc. MCRB is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has potential to become a first-in-class FDA-approved oral microbiome therapeutic.